The persistently high serum PTH and the accumulation of degradation fragments, a normal occurrence in CKD stages G2-G5, lead to desensitization of PTHR1, reducing the overall vasorelaxation potential on a systemic scale. This evidence concerns the gene PTH and chronic kidney disease.